新利18体育,18新利体育网页登录入口,18新利

Current Location:homepage  informations  doctordoctor

YUAN, SHENGTAO

Time:2017-12-30   Browse times:370

/_upload/article/images/a5/0b/bdf286c4440fbd00273ddd0a1488/28630b45-c3f6-4721-8bdd-9ce9bdafb57e.jpg

Research fellow

Doctoral advisor

Vice director of National Nanjing Center for Drug Screening and Jiangsu Key Laboratory for Drug Screening.

  

Working and Educational Experience:

2003-Present: Research fellow in National Nanjing Center for Drug Screening;

Member of Committee of Anti-Cancer Agent and Division of Tumor PharmacologyChinese Pharmacological Society;

Peer review expert of Department of Health Science, National Natural Science Foundation of China;

Expert reviewer of Postgraduate dissertations in Colleges, taster of SCI journal such as Oncotarget.

2002-2003: Visiting scholar at University of Helsinki.

1998-2001: Ph.D., Shanghai Institute of Materia Medica, Chinese Academy of Sciences,instructed by academician Jian Ding.

1996-1997: Research assistant, Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

1993-1996: Master of Science, Fudan University, instructed by Professor Xiqi Hu.

1990-1993: Bachelor of Medicine, Nanchang University, took the teaching post after graduation.

  

Honors & Awards:

Hold on three National Nature Science Foundation projects and one National High-tech R&D Program China (863 Program) sub-project. Hold on the funding project of Jiangsu Pharmacodynamic Research and Evaluation Service Center.

  

Take part in the National Science and Technology Major Project during the “11th Five-Year” and National Key Technology Research and Development Program of China during the 10th Five-Year Plan”. Take part in research projects such as National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, and Major New Drugs Innovation and Development.

  

Cooperate with Tasly Holding Group, Rongchang Pharmaceutical Ltd, Sanhome Pharmaceutical Ltd, Jiangsu Provincial Institute of Materia Medica, Jingjiang Lixi institute of Materia Medica, Dongnan University, Nanjing University of Science& Technology, Nanjing Tech University, Nanjing Foresty University and so on.

  

Have 30 corresponding author papers, SCI index; Won more than 20 patents; Won First Class Prizes of The State Scientific and Technological Progress Award in 2006; Engaged in new drug discovery and cooperate between colleges and enterprises, in 2013, a new type of anti-tumor medicine, DT-13, was transferred to Tasly Pharmaceutical Group for a total of 100 million Yuan.


新利18体育_18新利体育网页登录入口_18新利